



QIAGEN N.V.

Hulsterweg 82  
5912 PL Venlo  
The Netherlands

Tel. +31 77 35566-00  
Fax +31 77 35566-58  
qiagen@qiagen.com

[www.qiagen.com](http://www.qiagen.com)

Deutsche Trustee Company Limited  
Winchester House  
1 Great Winchester Street  
London, EC2N 2DB  
United Kingdom

Deutsche Bank AG, London Branch  
Winchester House  
1 Great Winchester Street  
London, EC2N 2DB  
United Kingdom

Global Treasury  
Tel. +31 (0) 77 355 6642  
[melanie.prang@qiagen.com](mailto:melanie.prang@qiagen.com)

Dear Sirs

30, January 2024

**Notification of Adjustment of Conversion Ratio under the QIAGEN N.V. 1.000% Senior Unsecured Convertible Notes due 2024 (the "Notes")**

We refer to the indenture dated as of November 13, 2018 in respect of the Notes between, amongst others, QIAGEN N.V. as issuer, Deutsche Trustee Company Limited as trustee and Deutsche Bank AG, London Branch as conversion agent (the "Indenture").

As required by Section 12.04(l) of the Indenture, we hereby notify you that as of the date hereof the Conversion Ratio has been adjusted to 4,356.8531. Such adjustment has been made pursuant to Section 12.04 of the Indenture to reflect the impact of the synthetic share repurchase. The synthetic share repurchase, which was approved in June 2023 at the Annual General Meeting of Shareholders, involves an approach used by various large, multinational Dutch companies as an efficient way to provide returns to all shareholders, and to do so in a faster and more efficient way than through a traditional open-market share repurchase program. It combines a direct capital repayment with a reverse stock split. Following the receipt of shareholder approval for the transaction, the Company observed a two-month creditor objection period as required under Dutch law.

The terms of the synthetic share repurchase are as follows: every 25 issued QIAGEN shares have been consolidated into 24.25 QIAGEN shares at close of business on January 29, 2024 and following the implementation of the consolidation, the Company will issue to its shareholders a capital repayment of \$1.28 per pre-split share held by each shareholder. Details of the settlement mechanics have been announced in a press release and SEC filing on January 18, 2024 which is attached hereto.

Capitalised terms not otherwise defined herein shall have the meaning given to them in the Indenture.

Yours faithfully

QIAGEN N.V.

Roland Sackers